Ascendis Pharma (Brazil) Performance
| A1SN34 Stock | BRL 48.42 0.00 0.00% |
Ascendis Pharma has a performance score of 8 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.15, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Ascendis Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ascendis Pharma is expected to be smaller as well. Ascendis Pharma AS right now shows a risk of 1.64%. Please confirm Ascendis Pharma AS market risk adjusted performance, semi deviation, variance, as well as the relationship between the mean deviation and downside deviation , to decide if Ascendis Pharma AS will be following its price patterns.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Ascendis Pharma AS are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Ascendis Pharma may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
| Begin Period Cash Flow | 584.5 M | |
| Total Cashflows From Investing Activities | -110.6 M |
Ascendis |
Ascendis Pharma Relative Risk vs. Return Landscape
If you would invest 4,356 in Ascendis Pharma AS on January 26, 2024 and sell it today you would earn a total of 486.00 from holding Ascendis Pharma AS or generate 11.16% return on investment over 90 days. Ascendis Pharma AS is generating 0.1867% of daily returns and assumes 1.6447% volatility on return distribution over the 90 days horizon. Simply put, 14% of stocks are less volatile than Ascendis, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Ascendis Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascendis Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ascendis Pharma AS, and traders can use it to determine the average amount a Ascendis Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1135
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | A1SN34 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.64 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Ascendis Pharma is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ascendis Pharma by adding it to a well-diversified portfolio.
Ascendis Pharma Fundamentals Growth
Ascendis Stock prices reflect investors' perceptions of the future prospects and financial health of Ascendis Pharma, and Ascendis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ascendis Stock performance.
| Return On Equity | -0.67 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (15.89) % | |||
| Current Valuation | 34.82 B | |||
| Shares Outstanding | 57.03 M | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 1,080 X | |||
| Revenue | 7.78 M | |||
| EBITDA | (364.64 M) | |||
| Book Value Per Share | 8.08 X | |||
| Cash Flow From Operations | (417.65 M) | |||
| Total Asset | 1.08 B | |||
About Ascendis Pharma Performance
To evaluate Ascendis Pharma AS Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Ascendis Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Ascendis Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Ascendis Pharma AS market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Ascendis's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Things to note about Ascendis Pharma AS performance evaluation
Checking the ongoing alerts about Ascendis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ascendis Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ascendis Pharma AS has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 7.78 M. Net Loss for the year was (383.58 M) with profit before overhead, payroll, taxes, and interest of 4.25 M. | |
| Ascendis Pharma generates negative cash flow from operations |
- Analyzing Ascendis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ascendis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Ascendis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ascendis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ascendis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ascendis Pharma's stock. These opinions can provide insight into Ascendis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Ascendis Pharma AS information on this page should be used as a complementary analysis to other Ascendis Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |